Muscle-invasive bladder cancer (MIBC) is one of the most aggressive forms of bladder surface cancer, characterized by tumor invasion into the underlying muscle of the organ. This type of cancer is usually classified by stages, where the tumor invades the muscle layer, which significantly worsens the prognosis and requires a more intensive treatment approach. From the time of diagnosis of MIBC, the involvement of adjacent tissues and the presence of metastases to lymph nodes and other organs often become a subject of discussion during the development of an effective treatment strategy. Muscle-invasive bladder cancer is associated with multiple factors, including smoking, chemical exposure and chemotherapeutic agents. To date, despite ongoing efforts to understand the mechanisms of the disease, the survival rate of patients with MIBC remains quite low, which emphasizes the importance of early diagnosis and individualized treatment.
History of the disease and interesting historical facts
The history of bladder cancer research dates back to ancient times. As early as 2000 BC, cases of bladder diseases were documented in Egypt. However, more detailed research began during the Renaissance, when scientists began to pay attention to anatomical and pathological changes. In the 19th century, a connection was identified between professions related to dye production and the development of bladder cancer. These scientific discoveries became the basis for further research into the etiology of the disease and its development.
Epidemiology
Overall, muscle-invasive bladder cancer occurs at a rate of 3-5 cases per 100,000 people per year. According to the latest data, approximately 200,000 new cases are diagnosed worldwide each year, with the disease being diagnosed more often in men than in women (ratio 3:1). The age groups most susceptible to the disease are people over 65 years of age. Research data show that the lifetime probability of developing MIBC in men is about 1 in 26, while in women this figure is lower - 1 in 88. Notably, in some regions, such as North America and Western Europe, the incidence is higher, which is associated with the prevalence of risk factors.
Genetic predisposition to this disease
Research shows that certain genetic mutations play an important role in the pathogenesis of muscle-invasive bladder cancer. The key genes involved are TP53, PTEN, FGFR3, and RB1. Mutations in the TP53 and RB1 genes are the most common and are associated with an aggressive course of the disease. In addition, in recent years, polymorphisms associated with the metabolism of chemicals and smoking have been identified that can increase the likelihood of developing MIBC. According to a study published in the journal Cancer Research, patients with a mutation in the FGFR3 gene are less likely to have disease progression.
Risk factors for the development of this disease
Risk factors that contribute to the development of muscle-invasive bladder cancer can be divided into several groups:
- Physical factors: high levels of exposure to ultraviolet radiation, bladder trauma.
- Chemical factors: contact with aromatic amines used in the production of dyes, rubber, as well as exposure to cadmium and arsenic.
- Medical factors: previous chemotherapy with cyclophosphamide or pelvic radiation.
- Lifestyle: Smoking is one of the main factors that increases the risk of developing the disease, increased alcohol consumption may also have an impact.
- Chronic diseases: certain infectious pathologies, such as chronic cystitis, may predispose to the development of a tumor.
Diagnosis of this disease
The main symptoms of muscle-invasive bladder cancer include:
- Hematuria (blood in the urine), which may be visible or microscopic.
- Frequent urination accompanied by discomfort.
- Pain in the lumbar and pelvic region.
- Fatigue and weight loss in later stages of the disease.
Basic laboratory tests for diagnosis include urine analysis for abnormal cells, biopsy, and cytology. Radiological tests such as ultrasound, CT, and MRI help visualize the tumor and determine the stage of the disease. Differential diagnosis includes ruling out infections, bladder stones, and other urological diseases.
Treatment
Treatment for muscle-invasive bladder cancer is usually complex and may include:
- General treatment: For patients with localized disease, surgery to remove the tumor is important, and if necessary, cystectomy is performed.
- Pharmacological treatment: includes the use of chemotherapy (eg, using suspensions of drugs based on mogadon and cisplatin) to reduce the likelihood of relapse.
- Surgical treatment: total or partial cystectomy, depending on the stage and location of the tumor. Modern methods such as laparoscopic and robotic surgery are used.
- Immunotherapy: New approaches such as anti-PD-1 and anti-PD-L1 drugs are showing promising results in clinical trials.
List of medications used to treat this disease
The list of drugs used includes:
- Cisplatin
- Mitomycin C
- Gemcitabine
- Ateolyzumab
- Pembrolizumab
- Nivolumab
Disease monitoring
Disease monitoring includes regular follow-up examinations focusing on recurrence and response to treatment. Prognosis depends on the stage of the disease, the presence of metastases, and the patient's general condition. Complications may include recurrence of the disease, development of metastases, and negative impact on bladder function and quality of life.
Age-related features of the disease
Muscle-invasive bladder cancer presents differently depending on age group. Older patients are more likely to be diagnosed at a later stage, while younger people tend to have more aggressive tumors. Older patients also have a higher risk of comorbidities, which can complicate treatment.
Questions and Answers
- What are the main symptoms of muscle invasive bladder cancer? The main symptoms are hematuria, frequent urination with discomfort, pain in the lumbar and pelvic region, and fatigue.
- What factors increase the risk of developing this disease? Risk factors include smoking, chemical exposure, chronic bladder infections, and age.
- What is the role of genetics in the development of muscle-invasive bladder cancer? Genetic mutations such as TP53 and RB1 play an important role in the pathogenesis of the disease, predisposing to the development of aggressive forms of the tumor.
- How is muscle invasive bladder cancer diagnosed? Diagnosis includes urine analysis, biopsy, radiological examinations (ultrasound, CT, MRI) and differential diagnosis to exclude other diseases.
- What are the current treatment options for MIBC? Treatment includes surgical methods (cystectomy), chemotherapy and immunotherapy using modern drugs to improve the prognosis.
